Abstract
In this work we report the tuberculostatic profile of a series of 5-phenyl-1,3,4-thiadiazole-2-arylhydrazone derivatives (1a-m). The evaluation of their in vitro antibacterial activity against Mycobacterium tuberculosis H37Rv was expressed as the minimum inhibitory concentration (MIC) in μg/mL. The compounds 1g and 1h exhibited inhibitory activity of 6.25 μg/mL and 1.25 μg/mL respectively, and can be considered as a good start point for the discovery of new lead compounds in the field of multi-drug resistant tuberculosis.
Keywords: 1,3,4-thiadiazoles, Antimycobacterial activity, N-arylhydrazones, Tuberculosis
Letters in Drug Design & Discovery
Title: Antimycobacterial Profile of 5-phenyl-1,3,4-thiadiazole-2-arylhydrazone Derivatives
Volume: 7 Issue: 8
Author(s): Samir A. Carvalho, Edson F. da Silva, Maria C.S. Lourenco, Marcus V.N. de Souza and Carlos A.M. Fraga
Affiliation:
Keywords: 1,3,4-thiadiazoles, Antimycobacterial activity, N-arylhydrazones, Tuberculosis
Abstract: In this work we report the tuberculostatic profile of a series of 5-phenyl-1,3,4-thiadiazole-2-arylhydrazone derivatives (1a-m). The evaluation of their in vitro antibacterial activity against Mycobacterium tuberculosis H37Rv was expressed as the minimum inhibitory concentration (MIC) in μg/mL. The compounds 1g and 1h exhibited inhibitory activity of 6.25 μg/mL and 1.25 μg/mL respectively, and can be considered as a good start point for the discovery of new lead compounds in the field of multi-drug resistant tuberculosis.
Export Options
About this article
Cite this article as:
A. Carvalho Samir, F. da Silva Edson, C.S. Lourenco Maria, V.N. de Souza Marcus and A.M. Fraga Carlos, Antimycobacterial Profile of 5-phenyl-1,3,4-thiadiazole-2-arylhydrazone Derivatives, Letters in Drug Design & Discovery 2010; 7 (8) . https://dx.doi.org/10.2174/157018010792062768
DOI https://dx.doi.org/10.2174/157018010792062768 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Preface
Current Drug Targets - Infectious Disorders Staphylococcus aureus: The Toxic Presence of a Pathogen Extraordinaire
Current Medicinal Chemistry MEFV Mutation Carriers and Diseases Other than Familial Mediterranean Fever: Proved and Non-Proved Associations; Putative Biological Advantage
Current Drug Targets - Inflammation & Allergy The Role of Vitamin D in Gastrointestinal Diseases: Inflammation, Gastric Cancer, and Colorectal Cancer
Current Medicinal Chemistry Machine Learning and Social Network Analysis Applied to Alzheimer's Disease Biomarkers
Current Topics in Medicinal Chemistry Bis(2-aminoimidazolines) and Bisguanidines: Synthetic Approaches, Antiparasitic Activity and DNA Binding Properties
Current Medicinal Chemistry Current Trends in Virtual High Throughput Screening Using Ligand-Based and Structure-Based Methods
Combinatorial Chemistry & High Throughput Screening Bibliometric Assessment of the Latin-American Contributions in Dengue
Recent Patents on Anti-Infective Drug Discovery Editorial (Thematic Issue: Recent Advances in the Structure-Based Drug Design and Discovery)
Current Topics in Medicinal Chemistry Managing the Liabilities Arising from Structural Alerts: A Safe Philosophy for Medicinal Chemists
Current Medicinal Chemistry Computational Sampling and Simulation Based Assessment of Novel <i>Mycobacterium tuberculosis</i> Glutamine Synthetase Inhibitors: Study Involving Structure Based Drug Design and Free Energy Perturbation
Current Topics in Medicinal Chemistry Infection-Associated Biomarkers of Inflammation in Atherosclerosis
Current Pharmaceutical Design A New Era of Pulmonary Delivery of Nano-antimicrobial Therapeutics to Treat Chronic Pulmonary Infections
Current Pharmaceutical Design Artificial Neural Networks to Optimize Formulation Components of a Fixed- Dose Combination of Rifampicin, Isoniazid and Pyrazinamide in a Microemulsion
Current Drug Discovery Technologies Polypharmacology in a Single Drug: Multitarget Drugs
Current Medicinal Chemistry Recombinant Murine Polyoma Virus-like-particles Induce Protective Antitumour Immunity
Letters in Drug Design & Discovery Design, Synthesis and Biological Evaluation of Carbazole Derivatives as Antitubercular and Antibacterial Agents
Current Bioactive Compounds Designing Type II Topoisomerase Inhibitors: A Molecular Modeling Approach
Current Topics in Medicinal Chemistry Pharmacological and Biological Activities of Xanthones
Anti-Infective Agents in Medicinal Chemistry The Implication of Pseudomonas aeruginosa Biofilms in Infections
Inflammation & Allergy - Drug Targets (Discontinued)